# Michel Briejer

> Michel Briejer is a seed investor at Thuja Capital backing Health Care and Biotechnology. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Thuja Capital](https://shizune.co/investors/profile/thuja-capital)
- Location: Utrecht, The Netherlands
- Total investments: 10
- Last investment: Dec 2025
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/mbriejer
- Website: http://thujacapital.com

Michel Briejer is a seed investor at Thuja Capital in Utrecht focused on Health Care and Biotechnology. Michel Briejer - Managing Partner @ Thuja Capital

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 40% |
| Biotechnology | 4 | 40% |
| Medical | 3 | 30% |
| Life Science | 1 | 10% |
| Neuroscience | 1 | 10% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 50% |
| Series A | 3 | 30% |
| Series B | 2 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| The Netherlands | 5 | 50% |
| Belgium | 1 | 10% |
| Germany | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pan Cancer T | Pan-Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T-cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors. | $5.8M | Seed | Dec 08, 2025 |  |
| Artica Therapeutics | Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food. | $12.7M | Seed | Nov 02, 2023 |  |
| FundaMental Pharma | FundaMental Pharma is a neuroscience company with a portfolio at the preclinical stage. | $10.4M | Seed | Nov 17, 2022 |  |
| EsoBiotec | EsoBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.EsoBiotec's objective is to enable the human body to fight cancer by delivering 'in vivo' cell engineering to patients. | $3.5M | Seed | Sep 30, 2021 |  |
| NutriLeads | NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiatescientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers. | $7.7M | Series B | Aug 30, 2020 |  |
| NutriLeads | NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiatescientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers. |  | Series A | Mar 29, 2017 |  |
| NutriLeads | NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiatescientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers. |  | Seed | Nov 18, 2015 |  |
| FABPulous | FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.FABPulous is a company based in The Netherlands. It was spun out of Maastricht University at the end of 2008. In December 2009 FABPulous closed a first equity financing round co-led by Thuja Capital, HealthInnovations, Limburg Ventures and NV Industriebank LIOF.The company has developed a technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages in the point-of-care (POC) and home testing setting, over current technology. It concerns a disposable plasma preparation device that can be integrated with many IVD detection platforms, such lateral flow devices. The first product application under development by FABPulous is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), to aid in the first-line diagnosis of acute myocardial infarction. |  | Series A | Jan 11, 2010 |  |
| Cavadis | CAVΛDIS™ is a Dutch biomedical company active in the field of cardiovascular risk assessment. They develop prognostic tests to identify patients at risk of cardiovascular and disease. The company identified several novel biomarkers predictive for cardiovascular events. It is their goal is to develop clinically meaningful risk stratification toolsthat will help personalize treatment and achieve better patient outcomes. |  | Series A | May 26, 2009 |  |
| FABPulous | FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.FABPulous is a company based in The Netherlands. It was spun out of Maastricht University at the end of 2008. In December 2009 FABPulous closed a first equity financing round co-led by Thuja Capital, HealthInnovations, Limburg Ventures and NV Industriebank LIOF.The company has developed a technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages in the point-of-care (POC) and home testing setting, over current technology. It concerns a disposable plasma preparation device that can be integrated with many IVD detection platforms, such lateral flow devices. The first product application under development by FABPulous is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), to aid in the first-line diagnosis of acute myocardial infarction. | $1.9M | Series B |  |  |

10 of 10 investments shown.

## Co-investors
- [DSM Venturing](https://shizune.co/investors/profile/dsm-venturing) — VC Fund, 3 deals together
- [SHIFT Invest](https://shizune.co/investors/profile/shift-invest) — VC Fund, 3 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 2 deals together
- [Health Innovation Fund](https://shizune.co/investors/profile/health-innovation-fund) — VC Fund, 2 deals together
- [InnovationQuarter](https://shizune.co/investors/profile/innovation-quarter) — VC Fund, 2 deals together
- [Limburg Ventures](https://shizune.co/investors/profile/limburg-ventures) — VC Fund, 2 deals together

## About Thuja Capital

VC Fund · Utrecht, The Netherlands

Thuja Capital invests in early stage medical product innovations for diagnosis, cure, care or prevention.

4 contacts available at Thuja Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Michel Briejer | Managing Partner | https://shizune.co/investors/profile/michel-briejer |
| Evan Castiglia | Partner | https://shizune.co/investors/profile/evan-castiglia |
| Florian Ludwig | Venture Partner | https://shizune.co/investors/profile/florian-ludwig-0542 |
| Harrold van Barlingen | Founder and Managing Partner | https://shizune.co/investors/profile/harrold-van-barlingen |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Michel Briejer invest in?

Michel Briejer invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Michel Briejer last invest?

The most recent investment recorded for Michel Briejer closed in Dec 2025. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co